Vector of glycated hemoglobin in the formation of dysglycemia in postmenopause: Emphasis on early diagnosis and therapy DOI Creative Commons
L. A. Ruyatkina, D. S. Ruyatkin, Л. В. Щербакова

и другие.

Meditsinskiy sovet = Medical Council, Год журнала: 2024, Номер 16, С. 135 - 147

Опубликована: Окт. 31, 2024

Introduction. The close relationship of postmenopause with insulin resistance (IR) and metabolic syndrome (MetS) marks a high cardiometabolic risk dysglycemia, determining the need for its early diagnosis therapy. Pathogenetically substantiated criteria prediabetes nature drug therapy type 2 diabetes mellitus (T2DM) are debated. Information on between glucose homeostasis parameters menopausal MetS is fragmentary. Aim. To evaluate associations glycated hemoglobin (HbA1c) levels indices IR, β-cell function character- istics in cohort postmenopausal women different carbohydrate states. Materials methods. In 94 Caucasian 58.0 (53.0; 63.0) years old following were determined: HbA1c, fasting glycemia (FG), TyG HOMA2 indices, C-peptid, BMI, waist circumference (WC), blood pressure (BP), triglycerides (TG), HDL-C levels. When classifying by HbA1c (ADA criteria), 15 had normoglycemia, 24 prediabetes, 55 T2DM. ME (25–75%) was assessed using SPSS (version 17); intergroup differences according to Mann – Whitney test; Spearman partial correlation analysis performed. Results. age independently correlated IR parameters: (R = 0.590; p < 0.001), HOMA2-IR 0.318; 0.05) beta cell function: HOMA2-B -0.355; 0.001); lipid markers (TG, HDL-C, respectively R 0.382; -0.448; anthropometric Conclusion . Associations spectrum mark it as vector formation progression dysglycemia due connection functional state β-cells importance lipoglucotoxicity dynamics IR. obtained data pathogenetically determine use verification administration combined antihyperglycemic aimed at preserving function. potential dipeptidyl peptidase-4 inhibitors slowing considered

Язык: Английский

Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice Using a Validated Liquid Chromatography–Tandem Mass Spectrometry Method DOI Creative Commons
Minyeong Pang, Jihoon Lee,

Min-Koo Choi

и другие.

Applied Sciences, Год журнала: 2025, Номер 15(3), С. 1445 - 1445

Опубликована: Янв. 31, 2025

Enavogliflozin, a sodium–glucose cotransporter 2 inhibitor, was approved in 2022 by the Korean Ministry of Food and Drug Safety as therapeutic agent for type diabetes mellitus has been investigated expanded efficacy diabetic retinopathy cardioprotection. In this study, we developed validated an analytical method to precisely detect enavogliflozin mouse plasma, employing liquid–liquid extraction combined with liquid chromatography–tandem mass spectrometry. Overall, method, covering range 5–3000 ng/mL, is reliable investigating time-concentration profiles enavogliflozin, demonstrating acceptable accuracy, precision, recovery, minimal matrix effects without stability concerns evidenced assessments post-treatment stability, freeze–thaw short-term enavogliflozin. Pharmacokinetic all pharmacokinetic parameters mice did not differ between fed fasted states after oral administration (1 mg/kg). Additionally, no differences were observed among single, 7-day repeated, 14-day repeated administrations at 1 mg/kg. tissue distribution showed highest kidneys, followed large intestine, stomach, small liver, heart, lungs, spleen, testes both 3 mg/kg doses. Dose proportionality except kidneys. conclusion, can be administered concern changes, regardless single or multiple dosing whether states. Furthermore, profile may offer valuable insights into potential drug.

Язык: Английский

Процитировано

0
The effect of empagliflozin and sitagliptin as an add-on therapy to metformin in blood pressure reduction in diabetic patients in primary health care settings in Riyadh, Saudi Arabia DOI Creative Commons

Mayada Ahmed,

Mohammed Altoyan,

Raghad Hijazi

и другие.

Journal of Family Medicine and Primary Care, Год журнала: 2025, Номер 14(3), С. 1116 - 1121

Опубликована: Март 1, 2025

A BSTRACT Background/Aim: Type 2 diabetes mellitus (T2DM) is a chronic condition. Metformin the first-line treatment, but if inadequate, sodium-glucose cotransporter-2 inhibitors (SGLT2i) or dipeptidyl peptidase-4 (DPP4i) are recommended as add-on therapies. This study aimed to directly compare effects of empagliflozin and sitagliptin therapies metformin in reducing blood pressure (BP) cohort type patients routine care. Additionally, assessed impact on HbA1c levels optimize antidiabetic medication selection for better BP control. Methods: retrospective was conducted at tertiary center Riyadh, Saudi Arabia, including diabetic aged 18–75. readings were compared 12- 24-week intervals. Patients had confirmed diagnosis T2DM, prescribed either Janumet Synjardy, least one reading within 3 months before 2–24 weeks after starting treatment. Exclusion criteria included antihypertensive use, changes, taking drugs other than metformin. Data demographics, vital signs, lab results. Results: The 44 participants, with mean age 55.73 years baseline 9.17%. Participants Synjardy (43.2%) (56.8%). No significant reduction systolic diastolic found. However, decreased from 9.17% 7.52% 6 months, greatest noted between months. Conclusion: Although neither drug significantly impacted BP, both combinations reduced HbA1c. Further research larger sample needed clarify their BP.

Язык: Английский

Процитировано

0
Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review DOI Creative Commons
М. В. Леонова

Consilium Medicum, Год журнала: 2024, Номер 26(4), С. 225 - 231

Опубликована: Май 20, 2024

Sodium-glucose cotransporter 2 inhibitors (SGLT-2) are a new class of hypoglycemic drugs that were initially approved for the treatment type diabetes. Currently, 5 in SGLT-2 by FDA glycemic control: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin and sotagliflozin. However, their effectiveness reducing risk heart failure progression chronic kidney disease was soon established, regardless diabetes status. In addition, according to number meta-analyses RCTs patients with cardiometabolic renal diseases, use reduces cardiovascular overall mortality serious adverse cardiac events outcomes or without diabetes, which is reflected indications use. Scientific data presented discussion mechanisms cardioprotective renoprotective effects class, many considered as pleiotropic not related effect on levels.

Язык: Английский

Процитировано

1
Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications DOI Creative Commons
Bogdan-Sorin Tudurachi, Larisa Anghel, Andreea Tudurachi

и другие.

Biomedicines, Год журнала: 2024, Номер 12(6), С. 1314 - 1314

Опубликована: Июнь 13, 2024

Myocardial infarction (MI) often leads to heart failure (HF) through acute or chronic maladaptive remodeling processes. This establishes coronary artery disease (CAD) and HF as significant contributors cardiovascular illness death. Therefore, treatment strategies for patients with CAD primarily focus on preventing MI lessening the impact of after an event. fibrosis, characterized by abnormal extracellular matrix (ECM) deposition, is central cardiac remodeling. Understanding these processes key identifying new targets. Recent studies highlight SGLT2 inhibitors (SGLT2i) GLP-1 receptor agonists (GLP1-RAs) favorable options in managing type 2 diabetes due their low hypoglycemic risk benefits. review explores inflammation’s role fibrosis evaluates emerging anti-diabetic medications’ effectiveness, such SGLT2i, GLP1-RAs, dipeptidyl peptidase-4 (DPP4i), post-acute MI. were analyzed identify effective medications reducing patients. By addressing areas, we can advance our understanding potential benefits post-MI improve patient outcomes individuals at HF.

Язык: Английский

Процитировано

1
Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection DOI Creative Commons
Francisco Epelde

Medicina, Год журнала: 2024, Номер 60(11), С. 1793 - 1793

Опубликована: Ноя. 1, 2024

The approach to managing type 2 diabetes mellitus (T2DM) has significantly progressed, evolving beyond strict glycemic control addressing the wider complications associated with disease, including cardiovascular disease (CVD) and chronic kidney (CKD) [...].

Язык: Английский

Процитировано

1
Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases DOI Creative Commons

Rongfang Pan,

Yuqing He,

Wan Melisandre

и другие.

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Окт. 30, 2024

Cardiovascular diseases (CVD) pose a significant threat to human health due their high mortality and morbidity rates. Despite advances in treatments, the prevalence impact of cardiovascular disease continue increase. Sodium-glucose transporter 2 inhibitors (SGLT2i), initially approved for treatment type diabetes, have important research value promising applications reducing CVD risk, especially heart failure (HF) atherosclerosis patients with (ASCVD). This study aims comprehensively review latest progress, trends, cutting-edge hot spots, future development directions SGLT2i field through bibliometric analysis.

Язык: Английский

Процитировано

0
Vector of glycated hemoglobin in the formation of dysglycemia in postmenopause: Emphasis on early diagnosis and therapy DOI Creative Commons
L. A. Ruyatkina, D. S. Ruyatkin, Л. В. Щербакова

и другие.

Meditsinskiy sovet = Medical Council, Год журнала: 2024, Номер 16, С. 135 - 147

Опубликована: Окт. 31, 2024

Introduction. The close relationship of postmenopause with insulin resistance (IR) and metabolic syndrome (MetS) marks a high cardiometabolic risk dysglycemia, determining the need for its early diagnosis therapy. Pathogenetically substantiated criteria prediabetes nature drug therapy type 2 diabetes mellitus (T2DM) are debated. Information on between glucose homeostasis parameters menopausal MetS is fragmentary. Aim. To evaluate associations glycated hemoglobin (HbA1c) levels indices IR, β-cell function character- istics in cohort postmenopausal women different carbohydrate states. Materials methods. In 94 Caucasian 58.0 (53.0; 63.0) years old following were determined: HbA1c, fasting glycemia (FG), TyG HOMA2 indices, C-peptid, BMI, waist circumference (WC), blood pressure (BP), triglycerides (TG), HDL-C levels. When classifying by HbA1c (ADA criteria), 15 had normoglycemia, 24 prediabetes, 55 T2DM. ME (25–75%) was assessed using SPSS (version 17); intergroup differences according to Mann – Whitney test; Spearman partial correlation analysis performed. Results. age independently correlated IR parameters: (R = 0.590; p < 0.001), HOMA2-IR 0.318; 0.05) beta cell function: HOMA2-B -0.355; 0.001); lipid markers (TG, HDL-C, respectively R 0.382; -0.448; anthropometric Conclusion . Associations spectrum mark it as vector formation progression dysglycemia due connection functional state β-cells importance lipoglucotoxicity dynamics IR. obtained data pathogenetically determine use verification administration combined antihyperglycemic aimed at preserving function. potential dipeptidyl peptidase-4 inhibitors slowing considered

Язык: Английский

Процитировано

0